Browse CENPF

Summary
SymbolCENPF
Namecentromere protein F, 350/400kDa
Aliases hcp-1; mitosin; centromere protein F, 350/400kDa (mitosin); CENF; CILD31; PRO1779; AH antigen; CENP-F kineto ......
Chromosomal Location1q41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, perinuclear region. Nucleus matrix. Chromosome, centromere, kinetochore. Cytoplasm, cytoskeleton, spindle. Note=Relocalizes to the kinetochore/centromere (coronal surface of the outer plate) and the spindle during mitosis. Observed in nucleus during interphase but not in the nucleolus. At metaphase becomes localized to areas including kinetochore and mitotic apparatus as well as cytoplasm. By telophase, is concentrated within the intracellular bridge at either side of the mid-body.
Domain PF10490 Rb-binding domain of kinetochore protein Cenp-F/LEK1
PF10473 Leucine-rich repeats of kinetochore protein Cenp-F/LEK1
PF10481 Cenp-F N-terminal domain
Function

Required for kinetochore function and chromosome segregation in mitosis. Required for kinetochore localization of dynein, LIS1, NDE1 and NDEL1. Regulates recycling of the plasma membrane by acting as a link between recycling vesicles and the microtubule network though its association with STX4 and SNAP25. Acts as a potential inhibitor of pocket protein-mediated cellular processes during development by regulating the activity of RB proteins during cell division and proliferation. May play a regulatory or permissive role in the normal embryonic cardiomyocyte cell cycle and in promoting continued mitosis in transformed, abnormally dividing neonatal cardiomyocytes. Interaction with RB directs embryonic stem cells toward a cardiac lineage. Involved in the regulation of DNA synthesis and hence cell cycle progression, via its C-terminus. Has a potential role regulating skeletal myogenesis and in cell differentiation in embryogenesis. Involved in dendritic cell regulation of T-cell immunity against chlamydia.

> Gene Ontology
 
Biological Process GO:0000070 mitotic sister chromatid segregation
GO:0000075 cell cycle checkpoint
GO:0000086 G2/M transition of mitotic cell cycle
GO:0000819 sister chromatid segregation
GO:0001655 urogenital system development
GO:0001822 kidney development
GO:0007059 chromosome segregation
GO:0007062 sister chromatid cohesion
GO:0007067 mitotic nuclear division
GO:0007088 regulation of mitotic nuclear division
GO:0007091 metaphase/anaphase transition of mitotic cell cycle
GO:0007093 mitotic cell cycle checkpoint
GO:0007094 mitotic spindle assembly checkpoint
GO:0007346 regulation of mitotic cell cycle
GO:0007517 muscle organ development
GO:0010389 regulation of G2/M transition of mitotic cell cycle
GO:0010639 negative regulation of organelle organization
GO:0010948 negative regulation of cell cycle process
GO:0010965 regulation of mitotic sister chromatid separation
GO:0014706 striated muscle tissue development
GO:0016202 regulation of striated muscle tissue development
GO:0021591 ventricular system development
GO:0030071 regulation of mitotic metaphase/anaphase transition
GO:0031577 spindle checkpoint
GO:0033044 regulation of chromosome organization
GO:0033045 regulation of sister chromatid segregation
GO:0033046 negative regulation of sister chromatid segregation
GO:0033047 regulation of mitotic sister chromatid segregation
GO:0033048 negative regulation of mitotic sister chromatid segregation
GO:0034508 centromere complex assembly
GO:0042493 response to drug
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044784 metaphase/anaphase transition of cell cycle
GO:0044839 cell cycle G2/M phase transition
GO:0045786 negative regulation of cell cycle
GO:0045839 negative regulation of mitotic nuclear division
GO:0045841 negative regulation of mitotic metaphase/anaphase transition
GO:0045930 negative regulation of mitotic cell cycle
GO:0048634 regulation of muscle organ development
GO:0050000 chromosome localization
GO:0051303 establishment of chromosome localization
GO:0051304 chromosome separation
GO:0051306 mitotic sister chromatid separation
GO:0051310 metaphase plate congression
GO:0051382 kinetochore assembly
GO:0051383 kinetochore organization
GO:0051640 organelle localization
GO:0051656 establishment of organelle localization
GO:0051783 regulation of nuclear division
GO:0051784 negative regulation of nuclear division
GO:0051983 regulation of chromosome segregation
GO:0051985 negative regulation of chromosome segregation
GO:0060537 muscle tissue development
GO:0065004 protein-DNA complex assembly
GO:0071173 spindle assembly checkpoint
GO:0071174 mitotic spindle checkpoint
GO:0071824 protein-DNA complex subunit organization
GO:0071897 DNA biosynthetic process
GO:0072001 renal system development
GO:0098813 nuclear chromosome segregation
GO:1901861 regulation of muscle tissue development
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902099 regulation of metaphase/anaphase transition of cell cycle
GO:1902100 negative regulation of metaphase/anaphase transition of cell cycle
GO:1902749 regulation of cell cycle G2/M phase transition
GO:2000816 negative regulation of mitotic sister chromatid separation
GO:2001251 negative regulation of chromosome organization
Molecular Function GO:0003682 chromatin binding
GO:0008022 protein C-terminus binding
GO:0008134 transcription factor binding
GO:0045502 dynein binding
Cellular Component GO:0000775 chromosome, centromeric region
GO:0000776 kinetochore
GO:0000777 condensed chromosome kinetochore
GO:0000779 condensed chromosome, centromeric region
GO:0000785 chromatin
GO:0000793 condensed chromosome
GO:0000922 spindle pole
GO:0000940 condensed chromosome outer kinetochore
GO:0005635 nuclear envelope
GO:0005813 centrosome
GO:0005819 spindle
GO:0005929 cilium
GO:0005930 axoneme
GO:0016363 nuclear matrix
GO:0030496 midbody
GO:0034399 nuclear periphery
GO:0036064 ciliary basal body
GO:0044441 ciliary part
GO:0045120 pronucleus
GO:0097014 ciliary plasm
GO:0097539 ciliary transition fiber
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-69275: G2/M Transition
R-HSA-68886: M Phase
R-HSA-68882: Mitotic Anaphase
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-68877: Mitotic Prometaphase
R-HSA-156711: Polo-like kinase mediated events
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663220: RHO GTPases Activate Formins
R-HSA-2500257: Resolution of Sister Chromatid Cohesion
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
Summary
SymbolCENPF
Namecentromere protein F, 350/400kDa
Aliases hcp-1; mitosin; centromere protein F, 350/400kDa (mitosin); CENF; CILD31; PRO1779; AH antigen; CENP-F kineto ......
Chromosomal Location1q41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CENPF and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCENPF
Namecentromere protein F, 350/400kDa
Aliases hcp-1; mitosin; centromere protein F, 350/400kDa (mitosin); CENF; CILD31; PRO1779; AH antigen; CENP-F kineto ......
Chromosomal Location1q41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CENPF in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.65 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCENPF
Namecentromere protein F, 350/400kDa
Aliases hcp-1; mitosin; centromere protein F, 350/400kDa (mitosin); CENF; CILD31; PRO1779; AH antigen; CENP-F kineto ......
Chromosomal Location1q41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CENPF in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6060.0358
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.220.874
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8980.445
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2630.567
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1830.935
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.370.903
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2050.672
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5990.756
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.2250.536
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7230.519
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3130.405
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5180.000154
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CENPF in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.76.8-3.11
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.76.8-3.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.817.6-12.80.307
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.727.3-19.60.3
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCENPF
Namecentromere protein F, 350/400kDa
Aliases hcp-1; mitosin; centromere protein F, 350/400kDa (mitosin); CENF; CILD31; PRO1779; AH antigen; CENP-F kineto ......
Chromosomal Location1q41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CENPF. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCENPF
Namecentromere protein F, 350/400kDa
Aliases hcp-1; mitosin; centromere protein F, 350/400kDa (mitosin); CENF; CILD31; PRO1779; AH antigen; CENP-F kineto ......
Chromosomal Location1q41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CENPF. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CENPF.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCENPF
Namecentromere protein F, 350/400kDa
Aliases hcp-1; mitosin; centromere protein F, 350/400kDa (mitosin); CENF; CILD31; PRO1779; AH antigen; CENP-F kineto ......
Chromosomal Location1q41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CENPF. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCENPF
Namecentromere protein F, 350/400kDa
Aliases hcp-1; mitosin; centromere protein F, 350/400kDa (mitosin); CENF; CILD31; PRO1779; AH antigen; CENP-F kineto ......
Chromosomal Location1q41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CENPF expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCENPF
Namecentromere protein F, 350/400kDa
Aliases hcp-1; mitosin; centromere protein F, 350/400kDa (mitosin); CENF; CILD31; PRO1779; AH antigen; CENP-F kineto ......
Chromosomal Location1q41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CENPF and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCENPF
Namecentromere protein F, 350/400kDa
Aliases hcp-1; mitosin; centromere protein F, 350/400kDa (mitosin); CENF; CILD31; PRO1779; AH antigen; CENP-F kineto ......
Chromosomal Location1q41
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CENPF collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.